Topical calcipotriol in the treatment of chronic plaque psoriasis in Bangladeshi skin

Authors

  • Agha Masood Choudhury
  • AZM Maidul Islam
  • SMMMA Ahad

Keywords:

Calcipotriol (DAIVONEX), psoriasis treatment, PASI

Abstract

Background Calcipotriol (DAIVONEX) ointment has been shown to be effective in thetreatment of chronic plaque psoriasis.Objective To assess the efficacy and safety of calcipotriol ointment (50μg/g) in the treatmentof chronic plaque psoriasis.Patients and methods A total of 61 patients (39 males, 22 females, age range from 18 to 76years) of chronic plaque psoriasis were enrolled in an open prospective trial. 51 completedthe study. Calcipotriol ointment was applied twice daily for up to 6 weeks on lesional area,following a 2 weeks washout phase with liquid paraffin. Efficacy, as measured by thePsoriasis Area and Severity Index (PASI), and safety were assessed at 2, 4 and 6 weeks.Results Reduction of PASI was statistically highly significant at all visits. The mean PASIfell in 6 weeks from 10.47 to 2.18 (P<0.001). Analysis of patient assessment at 6 weeksshowed total clearance in 8% of patients and marked improvement in 71% of patients. Theserum calcium level remained unchanged.Conclusion Topical application of 50μg/g calcipotriol ointment was found to be effective andsafe in the treatment of chronic plaque psoriasis.

References

Binderup L, Bramm E. effects of

a novel vitamin D analogue MC

on cell proliferation and

differentiation in vitro and on

calcium metabolism in vivo.

Biochem Pharmacol 1988; 37:

-95.

Kragballe K. MC 903. a noncalciotropic

vitamin D3 analogue

stimulates differentiation and

inhibits proliferation of cultured

human keratinocytes. J invest

Dermatol 1988; 91: 383 (Abstr).

Kragballe K, Beek HI, Segaard

H. Improvement of psoriasis by a

topical vitamin D3 analogue (MC

in a double blind study. Br J

Dermatol 1988; 119: 223-30.

Kragballe K. Treatment of

psoriasis by the topical

application of novel vitamin D3

analogue (MC 903). Arch

Dermatol 1989; 125: 1647-52.

Kragballe K, Gjertsen BT. De

Hoop D et al. Double-blind,

right/left comparison of

calcipotriol and betamethasone

valerate in treatment of psoriasis

vulgaris. Lancet 1991; 337: 193-

Cunliffe WJ, Berth-Jones J,

Claudy A et al. Comparative

study of calcipotriol (MC 903)

ointment and betamethasone 17-

valerate ointment in patients with

psoriasis vulgaris. J Am Acad

Dermatol 1992; 26: 736-43.

Berth-Jones J, Chu AC, Dodd

WAH et al. A multicentre

parallel group comparison of

calcipotriol ointment and short

contact dithranol therapy in

chronic plaque psoriasis. Br J

Dermatol 1992; 127: 266-71.

Frederiksson T, Petterson U. Oral

therapy with a new retinoid.

.Dermatologica 1978; 157: 238-

Darley CR, Cunliffe WJ, Green

CM et al. Safety and efficacy of

calcipotriol ointment

(DOVONEX) in treating children

with psoriasis vulgaris. Br J

Dermatol 1996; 135: 390-3.

SN Tham, KC Lun, WK Cheong.

A comparative study of

calcipotriol ointment and tar in

chronic plaque psoriasis. Br J

Dermatol 1994; 131: 673-7.

Dwyer C, Chapman RS.

Calcipotriol and hypercalcemia.

Lancet 1991, 338: 764-5.

Dubertrat L, Wallach D.

Souteyrand P et al. Efficacy and

safety of calcipotriol (MC 903)

ointment in psoriasis vulgaris. J

Am Acad Dermatol 1992; 27:

-8.

Klaber MR, Hutchinson PE,

Holden C et al. Long term

treatment of psoriasis with

calcipotriol. Br J Dermatol 1992;

(Suppl. 40):17 (abstract).

Downloads

Published

2017-01-03

How to Cite

1.
Choudhury AM, Islam AM, Ahad S. Topical calcipotriol in the treatment of chronic plaque psoriasis in Bangladeshi skin. J Pak Assoc Dermatol [Internet]. 2017Jan.3 [cited 2024Dec.5];14(4):215-9. Available from: https://jpad.com.pk/index.php/jpad/article/view/825

Issue

Section

Original Articles

Most read articles by the same author(s)